Vivos Therapeutics Inc. (NASDAQ: VVOS) stock surged by 1.51% at last close whereas the VVOS stock price tends to decline by 9.24% in the pre-market trading. Vivos Therapeutics Inc. is a medical technology company specializing in the development and commercialization of novel therapies for adult adults with sleep-disordered breathing, such as obstructive sleep apnea (OSA).
Financial Highlights
Vivos Therapeutics today announced the financial results and operating highlights for the first quarter ended March 31, 2021.
Discover Tomorrow's Stocks Today!
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
- Stay-at-Home Stocks Still A Healthy Investment?
- Best Solar Stocks To Buy As We Approach 2021
- The first quarter of 2021 brought in $3.4 million in revenue, rose 8% from the first quarter of 2020 when the revenue was $3.2 million.
- The first quarter of 2021 saw a gross profit of $2.7 million, an improvement of 11% from the first quarter of 2020’s gross profit of $2.4 million.
- In the first quarter of 2021, gross margin rose to 78 percent, up from 76 percent in the first quarter of 2020.
- In the first quarter of 2021, general and administrative costs were $5.1 million, compared to $4.2 million in the first quarter of 2020.
- The first quarter of 2021 saw a net loss of $3.4 million, compared to $2.6 million in the first quarter of 2020.
- Cash and cash equivalents totaled $14.1 million as of March 31, 2021, and cash was increased as a result of a $27.6 million underwritten follow-on sale in May 2021.
Business Outlook
- Vivos reached 17,000 total patients who are being treated with the Vivos System in the first quarter of 2021.
- AireO2, a new patient and sleep practice management automation application, was commercially launched in January 2021, according to VVOS.
- VVOS submitted a 510(k) application to the FDA in February 2021 for the Vivos mmRNA oral appliance, which is supposed to cure mild-to-moderate OSA.
- VivoScore, operated by SleepImage, a robust home sleep test product and service, was also launched in February 2021.
- VVOS opened the first Pneusomnia Center in March 2021, which is a clinician-owned, combined medical-dental sleep center that uses the Vivos System and is run by Vivos Therapeutics.
- VVOS has announced the launch of a new service called MyoCorrect in March, in which qualified professionals will offer orofacial myofunctional therapy through telemedicine to dentists participating in the Vivos Integrated Practice